Table 4.
Outcomes by Isolated Social Vulnerability Domain in Propensity Score-Matched Adults With HIV/HBV Coinfection
| Outcomes | Material vulnerability (N=568) | Healthcare vulnerability (N=1,780) | Interpersonal/Psychosocial vulnerability (N=614) | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Survival | ||||||
| All-cause mortality | 2.11 (1.17–3.81) | 0.012 | 3.23 (2.51–4.17) | <0.001 | 1.31 (0.77–2.21) | 0.317 |
| Liver disease and HBV viremia | ||||||
| Liver composite | 0.68 (0.41–1.14) | 0.138 | 1.57 (1.07–2.29) | 0.020 | 0.95 (0.61–1.48) | 0.826 |
| HBV DNA ≥2,000 IU/mL | 1.55 (0.70–3.42) | 0.274 | 1.49 (1.02–2.18) | 0.037 | 1.04 (0.46–2.36) | 0.934 |
| HIV disease control | ||||||
| HIV RNA >50 copies/mL | 2.09 (1.17–3.73) | 0.011 | 2.15 (1.62–2.85) | <0.001 | 1.05 (0.64–1.74) | 0.840 |
| CD4 count <200 cells/μL | 0.66 (0.35–1.26) | 0.202 | 1.57 (1.14–2.16) | 0.005 | 0.50 (0.26–1.01) | 0.068 |
| Extrahepatic outcomes | ||||||
| MACE | 1.7 (1.07–2.88) | 0.024 | 1.43 (1.05–1.95) | 0.023 | 1.76 (1.06–2.94) | 0.027 |
| CKD | 0.98 (0.53–1.82) | 0.942 | 1.71 (1.20–2.44) | 0.003 | 1.21 (0.77–1.89) | 0.412 |
| Diabetes | 1.04 (0.58–1.86) | 0.903 | 1.34 (1.03–1.75) | 0.031 | 1.01 (0.65–1.58) | 0.953 |
Hazard ratios compare adults with HIV/HBV coinfection with isolated single-domain social vulnerability with propensity score-matched adults with HIV/HBV coinfection and no documented social vulnerability. N indicates the total matched cohort size for each comparison; outcome-specific denominators may vary after exclusion of individuals with pre-follow-up evidence of the corresponding outcome. Interpersonal and psychosocial vulnerability domains were combined because of limited sample size. MACE indicates major adverse cardiovascular events; CKD, chronic kidney disease.